The National Institute for Health and Care Excellence (NICE) has issued a preliminary recommendation against the routine NHS commissioning of Gilead Sciences’ twice-yearly injectable pre-exposure prophylaxis (PrEP) medication, lenacapavir, marketed for prevention as Yeytuo. The decision, which is not yet final, has sparked immediate pushback from leading health advocates and HIV charities across the United Kingdom who warn the move could undermine national public health targets.
The evaluation committee concluded that the available clinical and economic evidence does not currently demonstrate that lenacapavir represents cost-effective value for money for the National Health Service (NHS) in England when compared against existing preventative options. Although the draft guidance recognizes the drug’s high efficacy in reducing HIV transmission rates relative to daily oral regimens, uncertainties surrounding trial demographics, real-world adherence modelling, and pricing negotiations ultimately drove the negative preliminary assessment.
The decision places a temporary roadblock in the path of what many medical professionals have hailed as a revolutionary advancement in infectious disease prevention. Stakeholders now look toward a pivotal second evaluation committee meeting scheduled for November 3, during which Gilead Sciences and health advocates hope to present revised pricing structures or supplementary data to alter the outcome.
Regulatory Timeline and the Evolution of Lenacapavir
The regulatory journey of lenacapavir has moved at a rapid pace globally, reflecting the high demand for long-acting preventative therapies. The drug’s active pharmaceutical ingredient first entered the UK clinical landscape in 2002 under the brand name Sunlenca, authorized as a treatment for multi-drug resistant HIV infections in combination with other antiretrovirals.
However, the expansion of lenacapavir into the preventative sphere represents a distinct therapeutic frontier. In June 2025, the US Food and Drug Administration (FDA) approved the twice-yearly injectable formulation under the brand name Yeztugo for pre-exposure prophylaxis. This milestone was followed in August 2025 by the European Commission’s marketing authorization for the product under the brand name Yeytuo.
Domestically, the UK’s Medicines and Healthcare products Regulatory Agency (MHRA) officially approved the PrEP indication for lenacapavir in December 2025. The approval was celebrated across the British medical community as a momentous step forward, offering an alternative to standard preventative care that could fundamentally shift patient compliance dynamics.
Despite these rapid international approvals, the divergence between regulatory clearance and health technology appraisal highlights the complex economic hurdles pharmaceutical innovations face before reaching patients within nationalized healthcare systems.
Understanding the Science and Clinical Promise of Yeytuo
To contextualize the debate surrounding NICE’s draft guidance, it is essential to examine the pharmacological mechanism and clinical profile of lenacapavir. As a capsid inhibitor, Yeytuo functions by disrupting the structural protein shell of the HIV-1 virus, interfering with multiple crucial stages of the viral lifecycle. Specifically, the drug inhibits viral capsid assembly and disassembly, nuclear import of viral DNA, and virus particle production, thereby preventing the virus from multiplying and establishing a systemic infection upon exposure.
Administered as a subcutaneous injection once every six months, lenacapavir addresses one of the most persistent challenges in preventative medicine: adherence. Traditional PrEP regimens predominantly rely on daily oral tablets, such as tenofovir disoproxil fumarate combined with emtricitabine (TDF/FTC). While highly effective when taken consistently, daily dosing schedules often suffer from poor long-term adherence driven by pill fatigue, lifestyle disruptions, or privacy concerns.
Clinical trial data submitted to regulatory bodies demonstrated that twice-yearly lenacapavir offers superior protection against HIV acquisition compared to standard daily oral options. By reducing the frequency of administration to biannual clinical visits, public health experts anticipated that the injectable would dramatically lower barriers to consistent preventative care, particularly among marginalized or vulnerable populations who struggle to maintain daily medication routines.
Economic Evaluations and NICE’s Rationale
The primary driver behind NICE’s preliminary negative recommendation is not a dispute over the biological efficacy of lenacapavir, but rather an issue of health economics and clinical uncertainty. In its preliminary guidance documentation, the NICE evaluation committee pointed to several key factors that complicated the cost-utility analysis.
First, the committee noted that while lenacapavir shows superior risk reduction compared to oral alternatives, the clinical trial populations did not universally align with the specific demographic and epidemiological profile of individuals at high risk of HIV acquisition in the UK. Consequently, determining the precise magnitude of benefit in an NHS setting introduced statistical variance.
Second, the appraisal committee raised questions regarding economic modelling assumptions. These included projections of how many individuals currently avoiding oral PrEP would actively uptake an injectable alternative, as well as the long-term quality-of-life impacts associated with avoiding chronic HIV infection.
Crucially, the price point proposed by Gilead Sciences did not align with the cost-effectiveness thresholds traditionally enforced by NICE for routine NHS adoption. Without an agreement on a more sustainable pricing framework or additional discounts, the committee concluded that funding the medication would impose a disproportionate financial burden relative to the health gains delivered, particularly given that alternative preventative technologies—such as GSK’s injectable cabotegravir (Apretude)—are already moving through or being evaluated within the UK healthcare framework.
Charities and Public Health Advocates Voice Profound Disappointment
The preliminary ruling by NICE triggered swift and coordinated pushback from the UK’s prominent HIV charities and advocacy organizations, who argue that penny-wise cost assessments threaten to derail national preventative milestones.
Richard Angell OBE, chief executive of the Terrence Higgins Trust, did not mince words regarding the decision. “We are profoundly disappointed by this initial decision by NICE,” Angell stated. “Twice-a-year injectable PrEP is the most exciting innovation in HIV prevention for years. PrEP is a gamechanger for HIV prevention and innovations like this must be jumped on and maximised—not kicked into the long grass and squandered.”
Echoing these sentiments, Daniel Fluskey, director of policy at the National AIDS Trust, emphasized the missed public health opportunities tied to pricing disputes. “We are deeply disappointed with the news today that a significant new HIV prevention drug will not yet be made available because of the failure to agree an affordable price,” Fluskey remarked. “The potential significance of lenacapavir is not in doubt. We believe it would save lives, reduce health inequalities, and go towards achieving the UK Government’s goal of ending new HIV transmissions by 2030.”
Broader Implications for the 2030 Elimination Target
The timing of NICE’s draft guidance intersects with ambitious national health policy objectives. The UK Government has formally committed to halting all new HIV transmissions and eliminating preventable AIDS-related deaths by the year 2030. Achieving this target requires aggressive deployment of biomedical intervention tools to suppress transmission vectors across high-risk cohorts.
Epidemiological data underscore the ongoing urgency of this mission. According to figures from the UK Health Security Agency, there were 6,402 new diagnoses of HIV recorded in the UK in 2023, with a total of 107,949 individuals actively receiving NHS HIV care during that same calendar year. While these numbers reflect historic advancements in treatment availability—ensuring that individuals living with suppressed viral loads cannot transmit the virus sexually—stopping new infections at the source remains the ultimate challenge.
Public health specialists argue that failing to incorporate long-acting injectables like lenacapavir into the national formulary could entrench existing health disparities. Populations experiencing higher rates of socio-economic deprivation, stigma, or unstable housing are often those least able to sustain daily oral medication schedules, yet they stand to benefit the most from a biannual preventative injection administered within a clinical setting. Without access to cutting-edge interventions, marginalized groups risk being left behind in the final push toward the 2030 zero-transmission goal.
Looking Ahead: The November Evaluation and Commercial Negotiations
Despite the discouraging initial verdict, the appraisal process is not finalized. The negative assessment issued by NICE constitutes a draft recommendation, designed to open a consultation window between the health watchdog, the manufacturer, clinical experts, and public health advocates.
A second evaluation committee meeting is formally scheduled for November 3. This upcoming session provides a critical window for Gilead Sciences to recalibrate its commercial proposals, potentially offering confidential patient-access schemes, managed entry agreements, or discounted pricing tiers that meet NICE’s cost-effectiveness criteria. Simultaneously, clinical experts and advocacy groups intend to submit supplementary real-world data and expert testimonies emphasizing the distinct value proposition of long-acting prevention in shrinking the pool of new HIV acquisitions.
As the healthcare sector awaits the November adjudication, the debate over lenacapavir serves as a broader bellwether for the modern pharmaceutical landscape. It underscores the perpetual tension between breakthrough biomedical innovation and fiscal stewardship within publicly funded healthcare systems. For thousands of individuals across England at risk of HIV, the outcome of these ongoing negotiations will determine whether a revolutionary preventative tool becomes an accessible standard of care or remains an unrealized promise.
